

On-going Progress Update and Disbursement Request

Instructions to the Principal Recipient for completing the On-going Progress Update and Disbursement Request

Progress Update

The *Progress Update* part of this form requires the Principal Recipient (PR) to provide:

- Past expenditure and programmatic performance information for the reporting period just ended
- An update on the progress made towards satisfaction of the conditions precedent (if any) set forth in Annex A to the Grant Agreement applicable to the period covered by the *Progress Update*
- A detailed Statement of Sources and Uses of Funds (Cash Flow Statement) for the reporting period just ended

For the Statement of Sources and Uses of Funds, the PR may use its own usual format and expenditure line items as derived from its budgeting and accounting records. The Global Fund does not prescribe specific expenditure line items, but prefers that the PR's reporting format is activity-based, in conformity with the proposal's objectives and service delivery areas. The PR is expected to clearly show actual expenditures as compared to budget for both its own expenditures as well as for disbursements to sub-recipients. The Statement of Sources and Uses of Funds should support the information disclosed in this form in Section 1.C (Program Expenditures) and Section 2.A (Cash Reconciliation for Period Covered by Progress Update).

Disbursement Request

The *Disbursement Request* part of this form requires the PR to state the cash requirement for meeting on-going program expenditures. The disbursement request from the Global Fund normally covers the PR's cash requirements for one reporting period, plus one additional quarter as a cash buffer, to ensure the PR has adequate cash on hand for program expenses at all times. The period covered by the *Disbursement Request* is the period that immediately follows the Reporting Period covered by the *Progress Update* (as explained above).

Upon completion, this form should be submitted (with supporting documentation) to the Local Fund Agent and copied to the Global Fund.

On-going Progress Update and Disbursement Request

GENERAL GRANT INFORMATION

Country:	Republic of Paraguay
Disease:	Tuberculosis
Grant Number:	PRY-S10-G05-T
Principal Recipient:	ALTER VIDA
Program Start Date:	1 DE JULIO 2010
Currency:	USD

PROGRESS UPDATE PERIOD

Progress Update - Reporting Period:	Cycle:	Semester	Number:	1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date:	31-Dec-2010
Progress Update - Number:	1			

DISBURSEMENT REQUEST PERIOD

Disbursement Request - Disbursement Period:	Cycle:	Semester	Number:	2
Disbursement Request - Period Covered:	Beginning Date:	1-Jan-2011	End Date:	30-Jun-2011
Disbursement Request - Number:	1			

TERMS AND ACRONYMS USED IN THIS PROGRESS UPDATE AND DISBURSEMENT REQUEST HAVE THE MEANING GIVEN TO THEM IN THE GRANT AGREEMENT RELATING TO THE ABOVE GRANT

Section 1: Programmatic and Financial Progress Update

A. PROGRAM PROGRESS

i. Program Objectives

Objective No.	Objective Description
1	R3. Strengthening the Laboratory network for smear-positive, culture and sensitivity testing for TB diagnosis and detection
2	R3. Consolidating quality DOTS in 18 health regions
3	R3. Implementing collaborative TB/HIV activities
4	R3. Developing Advocacy, Communication and Social Mobilisation strategies towards TB prevention and control
5	R7. Increasing universal access by means of quality diagnosis in indigenous communities while incorporating an intercultural focus
6	R7. Mitigating the socio-economic and cultural effects among individuals and the community of indigenous persons by providing patient-focused treatment
7	R7. Protecting indigenous populations from tuberculosis by strengthening advocacy, communication and social mobilization actions while maintaining an intercultural focus and empowering civil society
8	R7. Expanding the Stop- TB Strategy to Social Security health care providers (Institute of Social Security, Armed Forces Health Care and Police Health Care) in order to ensure the application of the strategy to the population covered by this system
9	R9. Continuing the expansion of a quality DOTS and improve it in the prisons
10	R9. Facing the TB/HIV co-infection in prisons
11	R9. Developing Advocacy, Communication and Social Mobilisation actions for the prevention and control of Tuberculosis
12	R9. Providing the opportunity to promote and carry out investigations

ii. Impact / Outcome Indicators

Impact / Outcome	Indicator Description	Baseline (if applicable)		Intended Yearly Targets	Actual Yearly Results	Reasons for deviation and any other comments	
		Value	Year				
Impact	1- TB Mortality Rate: Estimated number of deaths due to TB (all forms) per year per 100,000 population. de mortalidad por tuberculosis: Número anual registrado de muertes debido a la tuberculosis todas las formas por 100.000 habitantes.	1. Tasa	4.5/100,000	2007	NA	NA	El indicador será reportado en julio del año 2011
Impact	2- TB notification rate in indigenous communities in Paraguay. de notificación de la tuberculosis en población de comunidades indígenas del Paraguay.	2.- Tasa	368/100,000	2009	386/100000	332/100.000 (N° 393) Población indígena 2010: 1 18.279 Habitantes.	Se alcanzó 86 % de la meta prevista.
Impact	3- Tuberculosis prevalence rate in indigenous communities in Paraguay. prevalencia de la tuberculosis en población de comunidades indígenas del Paraguay.	3.- Tasa de	117.0/100,000	2009	N/A	NA	El indicador será reportado en julio del año 2011
Impact	4- Tuberculosis mortality rate in indigenous communities (all forms). mortalidad de la tuberculosis (todas las formas) en población de comunidades indígenas.	4.- Tasa de	15.8/100,000	2.009	NA	NA	El indicador será reportado en julio del año 2011
Outcome	1- Case Detection Rate: Percentage of new smear-positive TB patients reported to the national health authority among the new smear positive TB patients estimated to occur countrywide each year. 1.- Tasa de detección: Porcentaje de nuevos casos de tuberculosis con baciloscopia positiva notificados a la autoridad nacional sanitaria, entre nuevos casos de tuberculosis con baciloscopia positiva que se estiman que ocurrirán en todo el país.		69%	2008	74%	98% (1324/1350)	Se alcanzó 132 % % de la meta prevista.
Outcome	2- Treatment Success Rate: Percentage of new smear-positive TB patients successfully treated (cured plus completed treatment) among the new smear positive TB patients registered each year. 2.- Tasa de éxito del tratamiento: Porcentaje de nuevos casos de tuberculosis pulmonar con baciloscopia positiva que han completado con éxito el tratamiento (curación y tratamiento completo) entre los casos nuevos de tuberculosis pulmonar con baciloscopia positiva registrados cada año.		82%	2007	NA	NA	El indicador será reportado en julio del año 2011
Outcome	3- Treatment Success Rate: DOTS treatment success rate in indigenous communities. éxito de tratamiento bajo DOTTAES en paciente con TB pulmonar frote positivo de las poblaciones indígenas del Paraguay.	3.- Tasa de	83%	2008	NA	NA	El indicador será reportado en julio del año 2011
Outcome	4- Treatment success rate: Percentage of new smear-positive TB cases amongst prisoners successfully treated (cured plus completed treatment) among the new smear positive TB cases registered each year. 4.- Tasa de éxito de tratamiento: Porcentaje de nuevos casos de tuberculosis con baciloscopia positiva entre los presos tratados con éxito (curado + tratamiento terminado) entre los casos nuevos de tuberculosis con baciloscopia positiva registrados cada año.		82%	2008	NA	NA	El indicador será reportado en julio del año 2011
Select							
Select							
Select							
Select							

On-going Progress Update and Disbursement Request

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T			
Progress Update - Reporting Period:	Cycle:	Semester	Number:	1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date:	31-Dec-2010
Progress Update - Number:	1			

iii. Service Delivery Areas, Indicators, and Targets									
Objective No.	Service Delivery Area	Indicator Description	Directly Tied?	Level	Baseline (if applicable)		Intended Targets to date	Actual Results to date	Reasons for programmatic deviation and any other comments
					Value	Year			
1	Improving diagnosis	1.1 Number and percentage of laboratories showing adequate performance among those that received external quality assurance for smear microscopy. 1.1 Numero y porcentaje de laboratorios que muestran un funcionamiento adecuado entre todos los laboratorios que realizaron un control de calidad externo de la microscopia frotis.	No	2	90%	2008	NA	NA	
1	Improving diagnosis	1.2 Number and percentage of laboratories showing adequate performance among those that received external quality assurance for culture. 1.2 Numero y porcentaje de laboratorios que muestran un funcionamiento adecuado entre todos los laboratorios que realizaron un control de calidad externo del cultivo.	No	2	0	2008	NA	NA	
1	Improving diagnosis	1.3 Percentage of suspected cases examined by microscopy amongst the TB suspects reported. 1.3 Porcentaje de casos sospechosos de TB examinados a traves de baciloscopia.	No	3	85%	2008	87%	82.2% (14,018/17050)	Se logró 94,48 % de la meta esperada.
1	Procurement and supply management (first-line anti-TB drugs)	1.4 Number and percentage of MPHSHW health services reporting no stock-out of first-line anti TB drugs on the last day of the period. 1.4 Numero y Porcentaje de servicios de salud que reportan no desabastecimiento de medicamentos de primera linea en el último día del semestre.	No	2	20/967 2%	2008	96/967 (10)%	105/967 (10,9%)	Se logró 109,3 % de la meta esperada.
2	High quality DOTS	2.1 Case detection: Number of smear-positive TB cases detected under DOTS. detectado: Número y Porcentaje de casos nuevos de TBP BK (+) detectados bajo DOTS.	No	3	29%	2003	999	144% (1435/999)	Se logró 143,6 % de la meta esperada
2	High quality DOTS	2.2 Number and percentage of new smear-positive TB patients successfully treated (cured plus completed treatment) among the new smear positive TB patients registered during a specified period. 2.2 Porcentaje de pacientes nuevos, TB tratados exitosamente (curación y tratamiento completado) entre los nuevos pacientes TBPF+ registrados durante un periodo específico.	No	3	85%	2003	90%	85% (483/570)	Se logró 94,44 % de la meta esperada
2	Multidrug-resistant TB (MDR-TB)	2.3 Number of laboratory-confirmed MDR-TB patients enrolled in second line treatment. 2.3 Número de pacientes de MDR-TB confirmados en laboratorio con tuberculosis multi-drogo resistente (TB-MDR) ingresados a tratamiento de segunda línea.	Yes	3	0	2004	29	24	Se logró 82,75 % de la meta. Además de los 24 pacientes, se ha tratado con medicamentos de 2ª Línea, a 5 pacientes poli y mono resistentes, totalizando de ésta forma, 29 pacientes tratados con medicamentos de 2ª Línea.
2	Multidrug-resistant TB (MDR-TB)	2.4 Number and percentage of laboratory-confirmed MDR-TB patients successfully treated (cure plus completed treatment) among those enrolled in second-line anti-TB treatment during a specified period. 2.4 Número y porcentaje de pacientes de MDR-TB confirmados en laboratorio que han completado con éxito el tratamiento (curación y tratamiento completado) entre los registrados en el tratamiento de segunda línea durante un periodo específico.	No	3	0	2007	NA	NA	
2	High quality DOTS	2.5 Treatment abandonment rate (number and percentage) of new smear- positive cases detected under DOTS. 2.5 Tasa de abandono de tratamiento (numero y porcentaje) de casos nuevos de TBPF+ detectados bajo DOTS.	No	3	14%	2003	27/450 6%	5% (27/570)	Se logró el 83,3 % de la meta prevista.
2	TB/VIH	3.1 Number and percentage of TB patients who had and VIH test result recorded in the TB register among the total number of registered TB patients. 3.1 Numero y porcentaje de pacientes con tuberculosis sometidos a pruebas de deteccion del VIH entre el numero total de pacientes de TB registrados.	Yes	3	NA	NA	428 20%	570/2535 (22%)	Se logró el 133,17.
4	Advocacy, communication and social mobilization	4.1 Percentage of population with correct knowledge about TB (mode of transmission, symptoms, treatment and curability). 4.1 Porcentaje de la poblacion encuestada con conocimientos correctos sobre TB (modo de transmision, sintomas, tratamiento y curacion).	Yes	0	NA	2008	NA	NA	
5	High-risk groups	5.1 Number of new smear positive TB cases detected in indigenous populations. 5.1 Número de nuevos casos de tuberculosis con baciloscopia positiva detectados en poblaciones indígenas.	No	3	117	2007	144	106	Se logró 73,6 % de la meta prevista.

5	High Quality DOTS	5.2 Percentage of new smear positive TB cases successfully treated in indigenous populations. 5.2 Porcentaje de todos los casos nuevos, tuberculosis frotis positivo tratados exitosamente en poblaciones indígenas.	No	3	187 cases (81.7 % of 229 cases identified and treated)	2004	88%	89% (212/237)	Se logró 101,1 % de la meta prevista.
5	Improving diagnosis	5.3 Number of health units that carry out activities for the prevention and control of TB in indigenous communities. 5.3 Número de unidades de salud que llevan a cabo actividades para la prevención y el control de la tuberculosis en las comunidades indígenas.	No	2	26	2006	1.189	1.402	Se logró 117,9 % de la meta prevista.
6	Improving diagnosis	6.1 Number of health care, civil society organization professionals and other strategic actors working with indigenous communities in Paraguay trained in intercultural communication skills in order to implement the DOTS TB detection in indigenous communities. 6.1 Número de profesionales de la Salud y de ONGs de la sociedad civil y otros actores estratégicos que trabajan con comunidades indígenas del Paraguay, capacitados en habilidades de comunicación con enfoque intercultural para la implementación del DOTS / TAES para la detección de la TB en comunidades indígenas.	No	1	26	2006	794	1.185	Se alcanzó 149,2 % de la meta.
7	High-risk groups	7.1 Number of local and departmental health councils in which indigenous community representatives participate. 7.1 Número de consejos locales y departamentales de salud en los que participan representantes de comunidades indígenas.	No	2	1	2007	8	8	Se logró el 100 % de la meta prevista.
8	All care providers (PPM / ISTC - Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)	8.1 Number of health care services from the Social Security System (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas) undertaking detection, diagnosis and treatment within the DOTS Strategy framework. 8.1 Número de servicios de salud de la seguridad social (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas) participando en detección, diagnóstico y tratamiento directamente observado bajo la estrategia DOTS / TAES.	No	2	0	2007	40	46	Se alcanzó 115 % de la meta.
8	All care providers (PPM / ISTC - Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)	8.2 Number of new smear positive TB cases detected in patients who attend Social Security healthcare services (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas). 8.2 Número de nuevos casos de tuberculosis con baciloscopia positiva en pacientes que acuden a los servicios de salud de la seguridad social (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas).	No	3	0	2007	70	49	Se logró el 70 % de la meta prevista.
8	All care providers (PPM / ISTC - Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)	8.3 Percentage of new smear positive TB cases successfully treated in patients who attend Social Security healthcare services (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas). 8.3 Porcentaje de todos los casos nuevos, tuberculosis frotis positivo tratados exitosamente en pacientes que acuden a los servicios de salud de la seguridad social (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas).	No	3	0%	2007	85%	87% (52/60)	Se logró el 102,3 % de la meta prevista
9	High-risk groups	9.1 Number of new TB cases with positive bacilloscopy detected in prisons. 9.1 Número y porcentaje de casos nuevos de TB con baciloscopia (+) detectados en los centros penitenciarios.	No	3	152	2009	81	46	Se logró 56,7 % de la meta prevista.
9	Improving diagnosis	9.2 % of suspected cases examined by microscopy amongst the TB suspects reported in prisons. 9.2 Porcentaje de casos sospechosos de TB examinados a través de baciloscopia, reportados en las prisiones.	No	3	85,0%	2009	86%	95,3% (509/534)	Se alcanzó 110,8 % de la meta prevista.
9	High-risk groups	9.3 Percentage of smear positive TB patients in prisons successfully treated. 9.3 Porcentaje de casos de TB/PPL con baciloscopia (+) en pacientes que concluyen con éxito el tratamiento en centros penitenciarios.	No	3	83% (80/96)	2007	85%	73% (35/48)	Se logró 85,8 % de la meta prevista.
10	TB/HIV	10.1 Number and percentage of TB patients in prisons who had an HIV test result recorded in the TB register among the total number of registered TB patients in prisons. 10.1 Número y porcentaje de pacientes de TB sometidos a prueba de detección del VIH entre el número total de pacientes de TB registrados en prisiones.	No	3	3%	2008	30% (24/82)	42% (31/74)	Se alcanzó 140 % de la meta.
10	TB/HIV	10.2 Percentage of HIV/AIDS patients tested for TB in prisons. 10.2 Porcentaje de Pacientes con VIH/SIDA en quienes se investigó Tuberculosis en prisiones.	No	3	5%	2008	30% (7/25)	64% (16/25)	Se alcanzó 213 % de la meta
10	Infection Control	10.3 Number of prisons applying infection control measures, in accordance with national guidelines. 10.3 Número de centros penitenciarios que aplican medidas de control de infecciones de acuerdo con las directrices nacionales.	No	2	0	2009	0	NA	
11	ACSM (Advocacy, communication and social mobilization)	11.1 Number of prisoners that receive training in TB. 11.1 Número de PPL que recibe información sobre la tuberculosis.	No	0	0	2008	0	NA	

On-going Progress Update and Disbursement Request

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T		
Progress Update - Reporting Period:	Cycle:	Semester	Number: 1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date: 31-Dec-2010
Progress Update - Number:	1		

iv. Overall evaluation of performance

El contenido de ésta parte del informe se encuentra en el Anexo 1.

v. Planned changes in the program, if any.

El contenido de ésta parte del informe se encuentra en el Anexo 1.

vi. Other program results, success stories, issues or lessons learned

El contenido de ésta parte del informe se encuentra en el Anexo 1.

B. PR COMMENTS ON THE FULFILLMENT OF CONDITIONS PRECEDENT AND/OR SPECIAL CONDITIONS UNDER GRANT AGREEMENT

Conditions Precedent and/or other special conditions	Fulfilled? (Yes/No)	PR Comments
1. Conditions Precedent to First Disbursement in the Commitment Period (Terminal Date as stated in block 7A of the Face Sheet)	Yes	
2. Conditions Precedent to Second Disbursement in the Commitment Period (Terminal Date as stated in block 7B of the Face Sheet)	No	La respuesta será remitida en el transcurso de la presente semana.
3. Conditions Precedent to Disbursement for Procurement of second-line anti-tuberculosis drugs in the Commitment Period (Terminal Date as stated in block 7C of the Face Sheet)	Yes	
4. Conditions Precedent to Disbursement for the infrastructure improvements of the prisons of Tacumbú and Ciudad del Este, including the renovation works for the vocational training area in Tacumbú in the Commitment Period (Terminal Date as stated in block 7D of the Face Sheet)	No	Esta condición no ha podido cumplirse debido a dificultades con las cuales ha tropezado el Beneficiario Principal para dar cumplimiento a la misma, debido a problemas internos en la Penitenciaría de Tacumbú y al probable cierre de dicha penitenciaría. Se prevé cumplir con la misma en el transcurso del primer semestre del año 2.011.
C. SPECIAL TERMS AND CONDITIONS FOR THIS AGREEMENT	Select	
1. No later than 1 October 2010, the Principal Recipient shall submit to the Global Fund an action plan, in form and substance satisfactory to the Global Fund, to improve the Principal Recipient's program management capacities, including the Human Resources structure and procedures and Sub-recipient management. The improvement measures shall include, without limitation, the incorporation of additional treasury staff as well as staff for monitoring and auditing of disbursements to Sub-recipients. The Principal Recipient's Progress Update and Disbursement Request reports shall adequately demonstrate the state of implementation of the structure and the related oversight processes put in place.	Yes	Cumplido parcialmente. Mayores informaciones solicitadas por el Fondo Mundial serán remitidas en el transcurso de la presente semana.
2. No later than 1 October 2010, the Principal Recipient shall provide to the Global Fund evidence, in form and substance satisfactory to the Global Fund, of the measures put in place to strengthen and improve the Management Information System at all levels of the health system tasked with TB patient care and treatment.	No	La respuesta será remitida en el transcurso de la presente semana.
3. No later than 1 September 2010, the Principal Recipient shall provide to the Global Fund evidence, in form and substance satisfactory to the Global Fund, that the two principal recipients of Global Fund grant funds in Paraguay (as of the effective date of this Agreement, Altervida and CiRD), together with the Ministry of Health representatives, including those representing the TB National Sanitary Strategy, regional and local authorities, and the Country Coordinating Mechanism, have developed and are implementing a joint Coordination Plan for harmonization of procedures and activities aimed at fighting TB in Paraguay (the "Coordination Plan"). The Coordination Plan shall include, without limitation, measures to harmonize monitoring and evaluation procedures and activities. In order to follow-up on the implementation of the Coordination Plan, the Principal Recipient shall clearly identify and report on the activities undertaken for such coordination and communication in its progress updates and disbursement requests throughout the Commitment Period.	Yes	
4. No later than 1 October 2010, the Principal Recipient shall provide to the Global Fund evidence, in form and substance satisfactory to the Global Fund, of the finalization of the infrastructure and equipment works to improve the National Tuberculosis Program stores in order to ensure the quality of the Pharmaceutical Products procured by the Principal Recipient.	Yes	
5. No later than 30 November 2010, the Principal Recipient shall provide to the Global Fund a Human Resources Uptake Plan (the "Uptake Plan"), elaborated together with the Ministries and Institutions involved in the implementation of the Program and who have some of their Human Resources costs being partially paid for from Grant funds. The Uptake Plan shall respond to the need of sustainability of the interventions financed by this Program in the future and shall indicate how the uptake would be phased, describing how the following number of posts would be included in its institutional budget: a) 10 posts by 31 December 2011; and b) 10 additional posts by 31 December 2012.	No	Se han iniciado trámites para el efecto con el Ministerio de Salud, respecto al cual aun no se tiene respuesta. Se informará respecto a los avances en el transcurso de la presente semana.
6. The Principal Recipient acknowledges and agrees that the Terms of Reference of the Independent Audits to be performed on Grant funds spent under the terms of this Agreement, as well as for upcoming Independent Audits of funds spent under the Original Grant Agreements, shall include, in addition to the audit of funds spent at both Principal Recipient and Sub-recipient level and the review of internal controls at the Principal Recipient level, a review of the internal controls at Sub-recipient level.	Yes	Los Términos de referencia de la Auditorías Independientes incluyen la revisión de la aplicación de los controles internos a nivel del Beneficiario Principa, así como a nivel de los sub - beneficiarios.
7. The parties to this Agreement agree that the Global Fund will disburse US \$50,000 of Grant funds for each programmatic year of the Commitment Period directly to the Green Light Committee of the Stop TB Partnership for assistance with the procurement of pharmaceuticals for multi-drug resistance tuberculosis.	Yes	El Beneficiario Principal acepta el desembolso de US\$ 50.000 de los fondos de la subvención directamente para el Comité Luz Verde de la Asociación STOP - TB, para cada año programático del período de compromiso.

On-going Progress Update and Disbursement Request

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T		
Progress Update - Reporting Period:	Cycle:	Semester	Number: 1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date: 31-Dec-2010
Progress Update - Number:	1		

C. PROGRAM EXPENDITURES

All amounts are in: USD	Budget for Reporting Period	Actual for Reporting Period	Variance	Reason for Variance	Cumulative Budget through period of Progress Update	Actual through period of Progress Update	Variance	Reason for Variance
1. Total actual expenditures vs. budget	2.006.443,00	716.884,00	1.289.559,00		2.006.443,00	716.884,00	1.289.559,00	
1a. PR's total expenditures	1.408.310,00	544.054,00	864.256,00	La autorización para la implementación y los desembolsos fueron aprobados con atraso significativo	1.408.310,00	544.054,00	864.256,00	La autorización para la implementación y los desembolsos fueron aprobados con atraso significativo
1b. Disbursements to sub-recipients	598.133,00	172.830,00	425.303,00	La autorización para la implementación y los desembolsos fueron aprobados con atraso significativo	598.133,00	172.830,00	425.303,00	La autorización para la implementación y los desembolsos fueron aprobados con atraso significativo
2. Health product expenditures vs. budget <i>(already included in "Total actual" figures above)</i>	153.452,00	11.355,00	142.097,00		153.452,00	11.355,00	142.097,00	
2a. Pharmaceuticals	716,00	0,00	716,00	La compra paso para el siguiente periodo	716,00	0,00	716,00	La compra paso para el siguiente periodo
2b. Health products, commodities and equipment	152.736,00	11.355,00	141.381,00	La autorización para la implementación y los desembolsos fueron aprobados con atraso significativo	152.736,00	11.355,00	141.381,00	La autorización para la implementación y los desembolsos fueron aprobados con atraso significativo

Program expenditures were used for the procurement of health products:

No

If yes, information about procurements have been included in the Global Fund's Price Reporting Mechanism:

No

On-going Progress Update and Disbursement Request

DISBURSEMENT REQUEST PERIOD

Grant number:	PRY-S10-G05-T		
Disbursement Request - Disbursement Period:	Cycle:	Semester	Number: 2
Disbursement Request - Period Covered:	Beginning Date:	1-Jan-2011	End Date: 30-Jun-2011
Disbursement Request - Number:	1		

Section 2: Cash Reconciliation and Disbursement Request

A: CASH RECONCILIATION FOR PERIOD COVERED BY PROGRESS UPDATE

1. Cash Balance: Beginning of period covered by Progress Update (line 6 from Cash Reconciliation section of the period covered by the previous Progress Update):		414,653.00
Add:		
2. Cash disbursed to the PR by the Global Fund during the period covered by this progress update: ⁽¹⁾	2,011,546.00	
3. Interest received on bank account and other income received:	12,959.00	2,024,505.00
Less:		
4. Total program expenditures during period covered by Progress Update (value entered in Section 1C. "Total actual expenditures"):	716,884.00	
5. Other expenditures incurred (bank fees, other transaction costs, net exchange rate gains/losses):		716,884.00
6. Cash Balance: End of period covered by Progress Update:		1,722,274.00

B: DISBURSEMENT REQUEST

Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered by the Progress Update ^(2, 3):

7. Period beginning date:	1-Jan-2011	end date:	30-Jun-2011	amount as originally budgeted:	1,321,607.00	forecasted amount:	2,318,128.00
8. Additional quarter (cash "buffer") beginning date ⁽⁴⁾ :	1-Jul-2011	end date:	30-Sep-2011	amount as originally budgeted:	501,258.00	forecasted amount:	589,342.00
							2,907,470.00

Please explain any variance between the forecasted amounts and the amounts as originally budgeted

La diferencia esta dada por la reprogramacion del exedente del año 1 en USD 1.084.604, distribuidos en el semestre 2 (USD 996.520) y en el Trimestre 5 (USD 88.084)

Less:		1,722,274.00
9. Cash received from the Global Fund after the period covered by Progress Update or cash "in transit" ⁽⁵⁾ (if any):		1,722,274.00
10. PR's Disbursement Request from the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):		1,185,196.00

11. Does the PR's Disbursement Request include funds for health product procurement?

12. Exchange Rate (used to translate local currency into USD): 4766.00

Footnotes:

- 1 - Gross amount disbursed by the Global Fund (i.e., any associated bank fees or transaction costs should not be deducted in this line, but included in line 5. "Other expenditures incurred")
- 2 - Expenditures listed must be covered by current budget forecasts
- 3 - Total forecasted net cash expenditures should include any commitments made in the period covered by the Progress Update that are forecasted to be spent during the period covered by the Disbursement Request
- 4 - Additional period (cash "buffer"): disbursement of funds for Q9 is contingent upon the signing of Phase 2 or as otherwise stipulated per implementation letter
- 5 - "Cash in transit" includes amounts disbursed but not yet received by the PR and disbursement requests not yet approved by the Global Fund.

On-going Progress Update and Disbursement Request

GENERAL GRANT INFORMATION

Country:	Republic of Paraguay
Disease:	Tuberculosis
Grant number:	PRY-S10-G05-T
Principal Recipient:	ALTER VIDA
Program Start Date:	1 DE JULIO 2010
Currency:	USD

PROGRESS UPDATE PERIOD

Progress Update - Reporting Period:	Cycle:	Semester	Number:	1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date:	31-Dec-2010
Progress Update - Number:	1			

DISBURSEMENT REQUEST PERIOD

Progress Update - Reporting Period:	Cycle:	Semester	Number:	2
Progress Update - Period Covered:	Beginning Date:	1-Jan-2011	End Date:	30-Jun-2011
Progress Update - Number:	1			

Section 3: Cash Request and Authorization

A: CASH REQUEST

On behalf of the PR, the undersigned hereby requests the Global Fund to disburse funds under the above-referenced Grant Agreement as follows:

1. Cash amount requested from the Global Fund (from Section 2.B line 10, in: USD):

1.185.196,00

2. Amount requested in words (in: USD):

Dolares un millon ciento ochenta y cinco mil ciento noventa y seis

B: AUTHORIZATION

The undersigned acknowledges that: (i) all the information (programmatic, financial, or otherwise) provided in this Progress Update and Disbursement Request is complete and accurate; (ii) funds disbursed in accordance with this request shall be deposited in the bank account specified in block 9 of the face sheet of the Grant Agreement unless otherwise specified herein; and (iii) funds disbursed under the Grant Agreement shall be used in accordance with the Grant Agreement.

Signed on behalf of the Principal Recipient:
(signature of Authorized Designated Representative)

Name:

Miryan Caballero de Espinola

Title:

Directora

Date and Place:

Asuncion, 14 de Febrero de 2011

Bank Account Details (if different than the account details specified on block 9 of the face sheet of the Grant Agreement)

Owner of Bank Account:	Alter Vida
Account Title:	Alter Vida
Account number:	41.000.11.393
Bank name:	BANCO REGIONAL S.A.E.C.A.
Bank address:	Estrella esquina Alberdi
Bank SWIFT Code:	RGSAPYPE
Bank Code:	ABA 021000089
Routing instructions:	

Comments (e.g. changes to PR's bank account details, "split disbursements" to the PR and third parties etc.):

--

LFA On-going Progress Review and Disbursement Recommendation

Instructions to the LFA for completing the LFA On-Going Progress Review and Disbursement Recommendation

The Principal Recipient (PR) is required, through the *On-Going Progress Update and Disbursement Request*, to:

1. Provide past expenditure and programmatic performance information for the Reporting Period just ended; and
2. State its cash requirement for meeting on-going program expenditures.

The LFA is required, using this form, to verify progress and make recommendations on the cash amount requested.

Progress Update

The PR will report past expenditure and programmatic performance information for the Reporting Period just ended as well as progress made towards fulfillment of any conditions precedent/special conditions. The LFA is required to review and verify this information and, in accordance with the information fields set out in this form, to comment on current and cumulative progress.

Disbursement Recommendation

The PR will normally make a disbursement request from the Global Fund covering the PR's cash requirements for one Reporting Period, plus one additional quarter as a cash buffer, to ensure that the PR has adequate cash on hand for program expenses at all times. The Reporting Period for which the Disbursement Request is being made should be the period that immediately follows the Reporting Period covered by the PR's progress update (as explained above). The LFA is required to verify the PR's Cash Reconciliation and to ensure that the cash request is properly calculated. The LFA should recognize that the cash request should be based on the most up-to-date budgets for the relevant periods which the LFA should review for reasonableness.

Documents to be attached/retained

When submitting this form to the Global Fund, the LFA should attach the following:

1. *PR On-Going Progress Update and Disbursement Request* form (by email with originals to follow by mail)
2. Any supplementary information, as appropriate, to inform the Global Fund of the review and verification process and to support the review and recommendation

The LFA should also retain the PR's detailed Statement of Uses of Funds (Cash Flow Statement) for the Reporting Period just ended as well as any additional relevant documentation of verifications performed (to be provided upon request by the Global Fund).

LFA On-going Progress Review and Disbursement Recommendation

LFA Organization / Responsible office: _____

GENERAL GRANT INFORMATION

Country:	Republic of Paraguay
Disease:	Tuberculosis
Grant Number:	PRY-S10-G05-T
Principal Recipient:	ALTER VIDA
Program Start Date:	1 DE JULIO 2010
Currency:	USD

PROGRESS UPDATE PERIOD

Progress Update - Reporting Period:	Cycle:	Semester	Number:	1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date:	31-Dec-2010
Progress Update - Number:				1

DISBURSEMENT REQUEST PERIOD

Disbursement Request - Disbursement Period:	Cycle:	Semester	Number:	2
Disbursement Request - Period Covered:	Beginning Date:	1-Jan-2011	End Date:	30-Jun-2011
Disbursement Request - Number:				1

TERMS AND ACRONYMS USED IN THIS PROGRESS REVIEW AND DISBURSEMENT RECOMMENDATION HAVE THE MEANING GIVEN TO THEM IN THE GRANT AGREEMENT RELATING TO THE ABOVE GRANT

Section 1: LFA Review and Verification of the Principal Recipient's Programmatic and Financial Progress

A. PROGRAM PROGRESS

i. Program Objectives

Objective No.	Objective Description
1	R3. Strengthening the Laboratory network for smear-positive, culture and sensitivity testing for TB diagnosis and detection
2	R3. Consolidating quality DOTS in 18 health regions
3	R3. Implementing collaborative TB/HIV activities
4	R3. Developing Advocacy, Communication and Social Mobilisation strategies towards TB prevention and control
5	R7. Increasing universal access by means of quality diagnosis in indigenous communities while incorporating an intercultural focus
6	R7. Mitigating the socio-economic and cultural effects among individuals and the community of indigenous persons by providing patient-focused treatment
7	R7. Protecting indigenous populations from tuberculosis by strengthening advocacy, communication and social mobilization actions while maintaining an intercultural focus and empowering civil society
8	R7. Expanding the Stop- TB Strategy to Social Security health care providers (Institute of Social Security, Armed Forces Health Care and Police Health Care) in order to ensure the application of the strategy to the population covered by this system
9	R9. Continuing the expansion of a quality DOTS and improve it in the prisons
10	R9. Facing the TB/HIV co-infection in prisons
11	R9. Developing Advocacy, Communication and Social Mobilisation actions for the prevention and control of Tuberculosis
12	R9. Providing the opportunity to promote and carry out investigations

ii. Impact / Outcome Indicators

Impact / Outcome	Indicator Description	Intended Yearly Targets (from Attachment)	Actual Yearly Results (as reported by PR)	Verification Method	Modified Results (after verification)	LFA analysis on impact and outcome, any variance between (this should not be a "Copy and Paste" of the reasons for)
Impact	1.- TB Mortality Rate: Estimated number of deaths due to TB (all forms) per year per 100,000 population. 1. Tasa de mortalidad por tuberculosis: Número anual registrado de muertes debido a la tuberculosis todas las formas por 100.000 habitantes.	NA	NA	Select		
Impact	2.- TB notification rate in indigenous communities in Paraguay. 2.- Tasa de notificación de la tuberculosis en población de comunidades indígenas del Paraguay.	386/100000	332/100.000 (N° 393) Población indígena	Select		
Impact	3.- Tuberculosis prevalence rate in indigenous communities in Paraguay. Tasa de prevalencia de la tuberculosis en población de comunidades indígenas del Paraguay.	3.- N/A	NA	Select		
Impact	4.- Tuberculosis mortality rate in indigenous communities (all forms). Tasa de mortalidad de la tuberculosis (todas las formas) en población de comunidades indígenas.	4.- NA	N/A	Select		
Outcome	1.- Case Detection Rate: Percentage of new smear-positive TB patients reported to the national health authority among the new smear positive TB patients estimated to occur countrywide each year. 1.-	1	98% (1324/1350)	Select		
Outcome	2.- Treatment Success Rate: Percentage of new smear-positive TB patients successfully treated (cured plus completed treatment) among the new smear positive TB patients registered each year.	NA	N/A	Select		
Outcome	3.- Treatment Success Rate: DOTS treatment success rate in indigenous communities. Tasa de éxito de tratamiento bajo DOT/TAES en paciente con TB pulmonar frotis positivo de las poblaciones indígenas del Paraguay.	3.- NA	N/A	Select		
Outcome	4.- Treatment success rate: Percentage of new smear-positive TB cases amongst prisoners successfully treated (cured plus completed treatment) among the new smear positive TB cases registered each year. 4.-	NA	N/A	Select		
				Select		
				Select		
				Select		
				Select		

reen targets and results provided by the PR)

LFA On-going Progress Review and Disbursement Recommendation

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T		
Progress Update - Reporting Period:	Cycle:	Semester	Number: 1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date: 31-Dec-2010
Progress Update - Number:	1		

iii. Service Delivery Areas, Indicators, and Targets

Objective No.	Service Delivery Area	Indicator Description	Intended Targets to date (from Attachment)	Actual Results to date (as reported by PR)	Verification Method	Modified Results (after verification)	LFA analysis on progress to date, any variance between targets and results (this should not be a "Copy and Paste" of the reasons provided by the PR)
1	Improving diagnosis	1.1 Number and percentage of laboratories showing adequate performance among those that received external quality assurance for smear microscopy.	NA	NA	Select		
1	Improving diagnosis	1.2 Number and percentage of laboratories showing adequate performance among those that received external quality assurance for culture.	NA	NA	Select		
1	Improving diagnosis	1.3 Percentage of suspected cases examined by microscopy amongst the TB suspects reported. 1.3 Porcentaje de casos sospechosos de TB examinados a través de baciloscopia.	1	82,2% (14.018/17050)	Select		
1	Procurement and supply management (first-line anti-TB drugs)	1.4 Number and percentage of MPH/SW health services reporting no stock-out of first-line anti TB drugs on the last day of the period.	96/967 (10%)	105/967 (10,9%)	Select		
2	High quality DOTS	2.1 Case detection: Number of smear-positive TB cases detected under DOTS. 2.1 Caso detectado: Número y Porcentaje de casos nuevos de TBP BK (+) detectados bajo DOTS.	999	144% (1435/999)	Select		
2	High quality DOTS	2.2 Number and percentage of new smear-positive TB patients successfully treated (cured plus completed treatment) among the new smear positive TB patients registered during a specified period.	1	85% (483/570)	Select		
2	Multidrug-resistant TB (MDR-TB)	2.3 Number of laboratory-confirmed MDR-TB patients enrolled in second line treatment. 2.3 Número de pacientes de MDR-TB confirmados en laboratorio con tuberculosis multi-drogo resistente (TB-2.4 Number and percentage of laboratory-confirmed MDR-TB patients successfully treated (cure plus completed treatment) among those enrolled in second-line anti-TB treatment during a specified period.	29	24	Select		
2	Multidrug-resistant TB (MDR-TB)	2.4 Number and percentage of laboratory-confirmed MDR-TB patients successfully treated (cure plus completed treatment) among those enrolled in second-line anti-TB treatment during a specified period.	27/450	6%	Select		
2	#REF!	#REF!	#REF!	5% (27/570)	Select		
2	High quality DOTS	2.5 Treatment abandonment rate (number and percentage) of new smear-positive cases detected under DOTS.	428	20%	Select		
4	TB/VIH	3.1 Number and percentage of TB patients who had and VIH test result recorded in the TB register among the total number of registered TB patients.	NA	NA	Select		
5	#REF!	#REF!	144	106	Select		
5	Advocacy, communication and social mobilization	4.1 Percentage of population with correct knowledge about TB (mode of transmission, symptoms, treatment and curability).	1	#REF!	Select		
5	High-risk groups	5.1 Number of new smear positive TB cases detected in indigenous populations. 5.1 Número de nuevos casos de tuberculosis con baciloscopia positiva detectados en poblaciones indígenas.	1.189	#REF!	Select		
6	High Quality DOTS	5.2 Percentage of new smear positive TB cases successfully treated in indigenous populations. 5.2 Porcentaje de todos los casos nuevos, tuberculosis frotis positivo tratados exitosamente en poblaciones	794	#REF!	Select		
7	Improving diagnosis	5.3 Number of health units that carry out activities for the prevention and control of TB in indigenous communities.	#REF!	#REF!	Select		
8	Improving diagnosis	6.1 Number of health care, civil society organization professionals and other strategic actors working with indigenous communities in Paraguay trained in intercultural communication skills in order to implement the	#REF!	#REF!	Select		
8	High-risk groups	7.1 Number of local and departmental health councils in which indigenous community representatives participate.	8	89% (212/237)	Select		
8	All care providers (PPM / IStC - Public-Private Mix (PPM) approaches	8.1 Number of health care services from the Social Security System (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas) undertaking detection, diagnosis and treatment within the DOTS	40	49	Select		
9	All care providers (PPM / IStC - Public-Private Mix (PPM) approaches	8.2 Number of new smear positive TB cases detected in patients who attend Social Security healthcare services (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas).	70	#REF!	Select		
9	All care providers (PPM / IStC - Public-Private Mix (PPM) approaches	8.3 Percentage of new smear positive TB cases successfully treated in patients who attend Social Security healthcare services (Instituto de Previsión Social, Sanidad Militar, Sanidad Policial y Hospital de Clínicas).	1	95,3% (509/534)	Select		
9	High-risk groups	9.1 Number of new TB cases with positive bacilloscopy detected in prisons. 9.1 Número y porcentaje de casos nuevos de TB con baciloscopia (+) detectados en los centros	1	73% (35/48)	Select		
10	Improving diagnosis	9.2 % of suspected cases examined by microscopy amongst the TB suspects reported in prisons. 9.2 Porcentaje de casos sospechosos de TB examinados a través de baciloscopia, reportados en las prisiones.	30% (24/82)	42% (31/74)	Select		
10	High-risk groups	9.3 Percentage of smear positive TB patients in prisons successfully treated. 9.3 Porcentaje de casos de TB/PPL con baciloscopia (+) en pacientes que concluyen con éxito el tratamiento	30% (7/25)	1.185	Select		
10	TB/HIV	10.1 Number and percentage of TB patients in prisons who had an HIV test result recorded in the TB register among the total number of registered TB patients in prisons.	0	NA	Select		
11	TB/HIV	10.2 Percentage of HIV/AIDS patients tested for TB in prisons. 10.2 Porcentaje de Pacientes con VIH/SIDA en quienes se investigó Tuberculosis en prisiones.	0	NA	Select		
	Infection Control	10.3 Number of prisons applying infection control measures, in accordance with national guidelines/Number of prisons applying infection control measures, in accordance with national guidelines.			Select		
	ACSM (Advocacy, communication and social mobilization)	11.1 Number of prisoners that receive training in TB. 11.1 Número de PPL que recibe información sobre la tuberculosis.			Select		
					Select		
					Select		

LFA On-going Progress Review and Disbursement Recommendation

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T		
Progress Update - Reporting Period:	Cycle:	Semester	Number: 1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date: 31-Dec-2010
Progress Update - Number:	1		

B. LFA COMMENTS ON THE FULFILLMENT OF CONDITIONS PRECEDENT AND/OR SPECIAL CONDITIONS UNDER THE GRANT AGREEMENT

Conditions Precedent and/or other special conditions	Fulfilled?	LFA Analysis (this should not be a "Copy and Paste" of the comments provided by the PR)
1. Conditions Precedent to First Disbursement in the Commitment Period (Terminal Date as stated in block 7A of the Face Sheet)	Select	
2. Conditions Precedent to Second Disbursement in the Commitment Period (Terminal Date as stated in block 7B of the Face Sheet)	Select	
3. Conditions Precedent to Disbursement for Procurement of second-line anti-tuberculosis drugs in the Commitment Period	Select	
4. Conditions Precedent to Disbursement for the infrastructure improvements of the prisons of Tacumbú and Ciudad del Este.	Select	
C. SPECIAL TERMS AND CONDITIONS FOR THIS AGREEMENT	Select	
1. No later than 1 October 2010, the Principal Recipient shall submit to the Global Fund an action plan, in form and substance	Select	
2. No later than 1 October 2010, the Principal Recipient shall provide to the Global Fund evidence, in form and substance	Select	
3. No later than 1 September 2010, the Principal Recipient shall provide to the Global Fund evidence, in form and substance	Select	
4. No later than 1 October 2010, the Principal Recipient shall provide to the Global Fund evidence, in form and substance satisfactory to the Global Fund, of the finalization of the infrastructure and equipment works to improve the National Tuberculosis	Select	
5. No later than 30 November 2010, the Principal Recipient shall provide to the Global Fund a Human Resources Uptake Plan (the	Select	
6. The Principal Recipient acknowledges and agrees that the Terms of Reference of the Independent Audits to be performed on	Select	
7. The parties to this Agreement agree that the Global Fund will disburse US \$50,000 of Grant funds for each programmatic year	Select	

LFA On-going Progress Review and Disbursement Recommendation

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T		
Progress Update - Reporting Period:	Cycle:	Semester	Number: 1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date: 31-Dec-2010
Progress Update - Number:	1		

C. PROGRAM EXPENDITURES

All amounts are in: Please select currency on Page 1	Budget for Reporting Period	Actual for Reporting Period ¹	Variance	LFA Verified (Y/N)	LFA's Analysis of Variance (this should not be a "Copy and Paste" of the reasons provided by the PR)	Cumulative Budget through period of Progress Update	Actual through period of Progress Update	Variance	LFA's Analysis of Variance (this should not be a "Copy and Paste" of the reasons provided by the PR)
1. Total actual expenditures vs. budget	2,006,443,00	716,884,00	1,289,559,00			2,006,443,00	716,884,00	1,289,559,00	
1a. PR's total expenditures	1,408,310,00	544,054,00	864,256,00	Select		1,408,310,00	544,054,00	864,256,00	
1b. Disbursements to sub-recipients	598,133,00	172,830,00	425,303,00	Select		598,133,00	172,830,00	425,303,00	
2. Health product expenditures vs. budget <i>(already included in "Total actual" figures above)</i>	153,452,00	11,355,00	142,097,00	Select		153,452,00	11,355,00	142,097,00	
2a. Pharmaceuticals	716,00	0,00	716,00	Select		716,00	0,00	716,00	
2b. Health products, commodities and equipment	152,736,00	11,355,00	141,381,00	Select		152,736,00	11,355,00	141,381,00	

Program expenditures were used for the procurement of health products:

Select

If yes, information about procurements have been included in the Global Fund's Price Reporting Mechanism:

Select

LFA On-going Progress Review and Disbursement Recommendation

PROGRESS UPDATE PERIOD

Grant number:	PRY-S10-G05-T		
Progress Update - Reporting Period:	Cycle:	Semester	Number: 1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date: 31-Dec-2010
Progress Update - Number:	1		

D. LFA RATING AND COMMENTS ON PROGRAMMATIC AND FINANCIAL PROGRESS

1. LFA's Rating of PR's overall performance ⁽¹⁾ **Select**

2. Reasons for this Rating (including key issues and potential future risks):

3. LFA comments on PR planned changes in the program, if any (please refer to section 1.A.v of the PR's *Progress Update / Disbursement Request*):

4. LFA comments on data quality and reporting:

5. LFA comments on other program results, success stories, issues or lessons learned (please refer to section 1.A.vi of the PR's *Progress Update / Disbursement Request*):

1 - This rating should pertain to the cumulative progress (from the beginning of the Program to the end of the period covered by the Progress Update). It should take into consideration programmatic, financial and contextual factors.

- LFA ratings have been modified to be consistent with the Global Fund's new rating system. The new ratings relate to the previous ratings as follows:

New Scale		Old Scale	
Rating	Description	Rating	Description
A	Expected or exceeding expectations	5	Exceptional
		4	Expected
B1	Adequate	3	Minor adjustments needed
		2	Major adjustments needed
B2	Inadequate but potential demonstrated	1	Little progress made
		0	Major program issues
C	Unacceptable		

LFA On-going Progress Review and Disbursement Recommendation

DISBURSEMENT REQUEST PERIOD

Grant number:	PRY-S10-G05-T		
Disbursement Request - Disbursement Period:	Cycle:	Semester	Number: 2
Disbursement Request - Period Covered:	Beginning Date:	1-Jan-2011	End Date: 30-Jun-2011
Disbursement Request - Number:	1		

Section 2: LFA Review and Verification of the Principal Recipient's Cash Reconciliation and Disbursement Request

LFA COMMENTS ON THE CASH RECONCILIATION AND DISBURSEMENT REQUEST

1. The PR cash reconciliation is calculated correctly and is supported by a detailed Statement of Sources and Uses of Funds (i.e., Cash Flow statement):

Comments:

2. The PR Cash Request is calculated correctly and is supported by appropriate current budget forecasts:

Comments:

3. The LFA has identified expenditures (incurred or forecasted) that should not be financed by the Global Fund:

Comments:

4. The LFA has identified variance between the forecasted expenditures and the original budget for the disbursement period, including variance in line items:

Comments:

LFA On-going Progress Review and Disbursement Recommendation

DISBURSEMENT REQUEST PERIOD

Grant number:	PRY-S10-G05-T			
Disbursement Request - Disbursement Period:	Cycle:	Semester	Number:	2
Disbursement Request - Period Covered:	Beginning Date:	1-Jan-2011	End Date:	30-Jun-2011
Disbursement Request - Number:	1			

Section 3: LFA Recommendations and Review of Progress on Previous Recommendations

A. LFA RECOMMENDATIONS FOR THE CURRENT PROGRESS UPDATE AND DISBURSEMENT REQUEST

LFA Recommendations	Global Fund Decisions

B. LFA REVIEW OF PROGRESS ON PREVIOUS RECOMMENDATIONS CONFIRMED BY THE GLOBAL FUND

Previous Global Fund Decision	LFA Review of PR Progress

LFA On-going Progress Review and Disbursement Recommendation

LFA Organization / Responsible office: _____

GENERAL GRANT INFORMATION

Country:	Republic of Paraguay
Disease:	Tuberculosis
Grant Number:	PRY-S10-G05-T
Principal Recipient:	ALTER VIDA
Program Start Date:	1 DE JULIO 2010
Currency:	USD

PROGRESS UPDATE PERIOD

Progress Update - Reporting Period:	Cycle:	Semester	Number:	1
Progress Update - Period Covered:	Beginning Date:	1-Jul-2010	End Date:	31-Dec-2010
Progress Update - Number:	1			

DISBURSEMENT REQUEST PERIOD

Disbursement Request - Disbursement Period:	Cycle:	Semester	Number:	2
Disbursement Request - Period Covered:	Beginning Date:	1-Jan-2011	End Date:	30-Jun-2011
Disbursement Request - Number:	1			

Section 4: Disbursement Recommendation and Progress Review Summary

A. DISBURSEMENT RECOMMENDATION

1. Cash amount requested by the Principal Recipient from the Global Fund for next disbursement period plus one additional quarter (amount in: USD):

1.185.196,00

2. LFA disbursement recommendation (amount in: USD): _____

3. Reasons for the LFA's disbursement recommendation:

B. LFA RATING

LFA's rating of PR's overall progress

please select rating in
'LFA_Section 1.D.1'

C. VERIFICATIONS

The following information provided by the Principal Recipient in its *On-going Progress Review and Disbursement Request* has been verified:

Comments regarding verifications, if any:

- Select** Signature on behalf of Principal Recipient is authentic and the person to whom it belongs is authorized to sign the disbursement request
- Select** Conditions Precedent for disbursement and/or Special Conditions, if any, have been met (see Section 2, if applicable).
- Select** Program Expenditures and cash reconciliation have been verified and correspond with the PR's Statement of Sources and Uses of Funds (Cash Flow Statement).
- Select** Programmatic information provided by Principal Recipient in its On-going Progress Review and Disbursement Recommendation has been verified and corresponds with actual program progress.
- Select** Exchange rate stated by Principal Recipient has been verified and is correct.
- Select** Bank account information provided on the face sheet of Grant Agreement (Grant No. / Mod. No.): _____ (or as otherwise stated by the PR in its Progress Update / Disbursement Request) has been verified and is correct.
- Select** Current budget forecasts of the Principal Recipient for the next disbursement period plus one additional quarter have been reviewed for reasonableness

Signed on behalf of the LFA: _____

Name: _____

Title: _____

Date and Place: _____

OPTIONAL - insert image of

LFA signature here*:

(the size should not exceed
the limit of cells B2:D2)

* In every case, the LFA should provide a bona fide signature (in LFA Section 4) on the original (paper-based) LFA report, sent to the Global Fund by mail.